Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $17.80 Consensus PT from Analysts
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) has been given a consensus recommendation of “Buy” by the six analysts that are currently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have updated their coverage on the stock […]
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) has been given a consensus recommendation of “Buy” by the six analysts that are currently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have updated their coverage on the stock […]
